Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Biotech industry may not be well represented on the new National Science Advisory Board for Biosecurity, but they will be watching closely from the sidelines.
Can developing countries benefit from the drugs that are tested in their territory by virtual company outsourcing every step of the making of medicine there? Haseltine's recent experiences in India made him believe it is possible.
Malaysia is embarking on an ambitious 15-year plan to foster a local biotech industry, but can it compete with countries like India and China, already engaged in the industry?
With follow-on biologics in the United States still stuck in regulatory purgatory, Israeli genericsgiant Teva Pharmaceuticals is forging ahead in biogenerics through a Chinese acquisition.
Conventional wisdom is that biotech floatations in Europe belong on the London stock market. But the CEO of the Swiss stock exchange is bullish about the advantages of his exchange for life science ventures.
Ambitious plans by the European Commission (EC) to double research spending during 2007–2013 were quietly shelved during the run-up to a political summit of EU heads of state on June 15–16.
The clinical trials market is opening up in China. The most recent evidence has been provided by the opening of the Danish Centre for Clinical and Basic Research (CCBR) in Beijing